HIK Stock Overview
Develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Hikma Pharmaceuticals PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£19.36 |
| 52 Week High | UK£21.65 |
| 52 Week Low | UK£17.11 |
| Beta | 0.41 |
| 11 Month Change | -6.47% |
| 3 Month Change | -3.15% |
| 1 Year Change | -7.81% |
| 33 Year Change | -18.89% |
| 5 Year Change | -7.37% |
| Change since IPO | 586.52% |
Recent News & Updates
Recent updates
Hikma Pharmaceuticals PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 11
Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 36% Below Their Intrinsic Value Estimate
Aug 01Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price
Jun 02Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Feb 21Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 24These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well
Jun 06Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Feb 26Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price
Dec 01Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?
Nov 11Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?
Sep 02Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Aug 09Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate
May 21Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly
May 03It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year
Apr 16How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?
Apr 13Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend
Mar 14Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28Shareholder Returns
| HIK | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -0.4% | -4.4% | 1.1% |
| 1Y | -7.8% | 8.4% | 5.8% |
Return vs Industry: HIK underperformed the UK Pharmaceuticals industry which returned 8.4% over the past year.
Return vs Market: HIK underperformed the UK Market which returned 5.8% over the past year.
Price Volatility
| HIK volatility | |
|---|---|
| HIK Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 9.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: HIK has not had significant price volatility in the past 3 months.
Volatility Over Time: HIK's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 9,100 | Riad Mishlawi | www.hikma.com |
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.
Hikma Pharmaceuticals PLC Fundamentals Summary
| HIK fundamental statistics | |
|---|---|
| Market cap | UK£4.29b |
| Earnings (TTM) | UK£217.16m |
| Revenue (TTM) | UK£2.30b |
19.8x
P/E Ratio1.9x
P/S RatioIs HIK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HIK income statement (TTM) | |
|---|---|
| Revenue | US$3.02b |
| Cost of Revenue | US$1.57b |
| Gross Profit | US$1.45b |
| Other Expenses | US$1.16b |
| Earnings | US$285.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.29 |
| Gross Margin | 47.99% |
| Net Profit Margin | 9.45% |
| Debt/Equity Ratio | 53.2% |
How did HIK perform over the long term?
See historical performance and comparison